xene-8k_20170324.htm

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): March 24, 2017

 

XENON PHARMACEUTICALS INC.

(Exact name of Registrant as Specified in Its Charter)

 

 

Canada

001-36687

98-0661854

(State or Other Jurisdiction

of Incorporation)

(Commission File Number)

(IRS Employer Identification No.)

 

 

 

200-3650 Gilmore Way

Burnaby, British Columbia V5G 4W8

Canada

(Address of principal executive offices including zip code)

 

(604) 484-3300

(Registrant’s telephone number, including area code)

 

 

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 

 


 

 

Item 8.01

Other Events

On March 24, 2017, Xenon Pharmaceuticals Inc. (the “Company”) issued a press release announcing results from the double-blind, multi-center, vehicle-controlled, parallel-group study designed to evaluate the efficacy, safety, tolerability and systemic exposure of XEN801 for the treatment of moderate to severe facial acne.  A copy of the Company’s press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.  

 

Item 9.01

Financial Statements and Exhibits

(d) Exhibits.

 

Exhibit Number

Description

99.1

Press Release issued by Xenon Pharmaceuticals Inc. dated March 24, 2017.

 


 


 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

 

Xenon Pharmaceuticals Inc.

 

 

 

 

Date:  March 24, 2017

 

By:

/s/ Ian Mortimer

 

 

 

Ian Mortimer

 

 

 

Chief Financial Officer & Chief Operating Officer


 


 

EXHIBIT INDEX

Exhibit Number

Description

99.1

Press Release issued by Xenon Pharmaceuticals Inc. dated March 24, 2017.